MMED (Minimed Group) ROCE %: -9.88% (As of Jan. 2026)


MMED Minimed Group Inc MMED
15 GF Score
Price $14.28
! 1 Warning Sign
View Full Analysis

What is Minimed Group ROCE %?

Minimed Group MMED +0.14% 15 ROCE % is -9.88% as of Jan. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Minimed Group's annualized ROCE % for the quarter that ended in Jan. 2026 was -9.88%.

Minimed Group  (NAS:MMED) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Minimed Group ROCE % Related Terms

Minimed Group ROCE % Historical Data

* Premium members only.

The historical data trend for Minimed Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group ROCE % Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25
ROCE %
0.00 -1.93 -1.02

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26
ROCE % 0.00 2.46 -4.35 0.00 -9.88
MMED
15GF Score
Minimed Group Inc MMED
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group ROCE % Calculation

Minimed Group's annualized ROCE % for the fiscal year that ended in Apr. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Apr. 2025 )  (A: Apr. 2024 )(A: Apr. 2025 )
=-36/( ( (4094 - 518) + (4201 - 710) )/ 2 )
=-36/( (3576+3491)/ 2 )
=-36/3533.5
=-1.02 %

Minimed Group's ROCE % of for the quarter that ended in Jan. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jan. 2026 )  (Q: Oct. 2025 )(Q: Jan. 2026 )
=-372/( ( (4235 - 350) + (4343 - 696) )/ 2 )
=-372/( ( 3885 + 3647 )/ 2 )
=-372/3766
=-9.88 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -9.88% mean?
Minimed Group (MMED) has a ROCE % of -9.88% as of Jan. 2026.
Is Minimed Group's ROCE % too high?
Minimed Group's current ROCE % is -9.88%. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's ROCE % compare to ICUI and WRBY?
Minimed Group's ROCE % of -9.88% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current ROCE % is -9.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current ROCE % of -9.88%. The current ROCE % is -9.88%. Minimed Group's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Minimed Group (MMED), the current ROCE % is -9.88% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges B8S:Germany
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for MMED

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.28
Price